Abstract
The current diagnostic threshold for diabetes mellitus is imposed on a continuous distribution of blood glucose measurement. A more clinical approach estimates a threshold above which the rate of diabetes-specific complications rises steeply. However, the diagnostic threshold for diabetes is essentially established on the risk of microvascular and not cardiovascular complications. Indeed, while there appears to be a continuous relationship between blood glucose, cardiovascular risk and overall mortality, this association extends into the sub-diabetic range, with no threshold identified. In this regard, the assumption that the diagnosis of diabetes can effectively identify patients at elevated risk of cardiovascular morbidity and mortality is potentially flawed, and questions the utility of diabetes status (as a dichotomous variable) for the assessment and management of cardiovascular risk. Indeed, the increased risk of cardiovascular complications may not be related to diabetes status per se but the frequent association of diabetes with a high-risk phenotype, now recognised as the so-called ‘metabolic syndrome’. By implication, cardiovascular disease prevention should not be dominated by a drive for the prevention of diabetes, but this broader clinical syndrome of increased cardiovascular risk.
Keywords: oral glucose tolerance testing, cardiovascular risk, dyslipidaemia, International Diabetes Federation, metabolic syndrome
Current Pharmaceutical Design
Title: From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Volume: 13 Issue: 25
Author(s): Hoong Sern Lim and Gregory Y.H. Lip
Affiliation:
Keywords: oral glucose tolerance testing, cardiovascular risk, dyslipidaemia, International Diabetes Federation, metabolic syndrome
Abstract: The current diagnostic threshold for diabetes mellitus is imposed on a continuous distribution of blood glucose measurement. A more clinical approach estimates a threshold above which the rate of diabetes-specific complications rises steeply. However, the diagnostic threshold for diabetes is essentially established on the risk of microvascular and not cardiovascular complications. Indeed, while there appears to be a continuous relationship between blood glucose, cardiovascular risk and overall mortality, this association extends into the sub-diabetic range, with no threshold identified. In this regard, the assumption that the diagnosis of diabetes can effectively identify patients at elevated risk of cardiovascular morbidity and mortality is potentially flawed, and questions the utility of diabetes status (as a dichotomous variable) for the assessment and management of cardiovascular risk. Indeed, the increased risk of cardiovascular complications may not be related to diabetes status per se but the frequent association of diabetes with a high-risk phenotype, now recognised as the so-called ‘metabolic syndrome’. By implication, cardiovascular disease prevention should not be dominated by a drive for the prevention of diabetes, but this broader clinical syndrome of increased cardiovascular risk.
Export Options
About this article
Cite this article as:
Lim Sern Hoong and Lip Y.H. Gregory, From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663028
DOI https://dx.doi.org/10.2174/138161207781663028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Oxidative Stress and Inflammation: Their Role in the Pathogenesis of Peripheral Artery Disease with or Without Type 2 Diabetes Mellitus
Current Vascular Pharmacology What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Insulin Resistance and Postprandial Hyperglycemia the Bad Companions in Natural History of Diabetes: Effects on Health of Vascular Tree
Current Diabetes Reviews Flavonoid Enriched Fraction of Campylandra aurantiaca Attenuates Carbon Tetrachloride Induced Oxidative DNA Damage in Mouse Peritoneal Macrophages in Animal Model
Current Drug Discovery Technologies Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Novel Subtype Specific and Universal Somatostatin Analogues: Clinical Potential and Pitfalls
Current Pharmaceutical Design Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Reperfusion Therapies for Acute Ischemic Stroke: An Update
Current Cardiology Reviews Magnesium in Pain Research: State of the Art
Current Medicinal Chemistry Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design